SPC Logo

Arava 20mg Tablets

Last Updated on eMC 07-Nov-2014 View document  | SANOFI Contact details

When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC.  For each version, we show the dates it was published on the eMC and the reasons for change.

Updated on 07-Nov-2014 and displayed until Current

Reasons for adding or updating:

  • Change to section 2 - what you need to know - contraindications
  • Change to section 2 - what you need to know - warnings and precautions
  • Change to section 2 - use in children/adolescents
  • Change to section 2 - interactions with other medicines, food or drink
  • Change to section 4 - how to report a side effect
  • Change to section 6 - date of revision

Updated on 30-May-2014 and displayed until 07-Nov-2014

Reasons for adding or updating:

  • Change to section 2 - what you need to know - warnings and precautions
  • Change to section 4 - possible side effects

Updated on 20-Feb-2014 and displayed until 30-May-2014

Reasons for adding or updating:

  • Change to section 4 - how to report a side effect

Updated on 12-Apr-2013 and displayed until 20-Feb-2014

Reasons for adding or updating:

  • Change to section 2 - what you need to know - warnings and precautions
  • Change to section 4 - possible side effects

Updated on 23-May-2012 and displayed until 12-Apr-2013

Reasons for adding or updating:

  • Change to warnings or special precautions for use

Updated on 24-May-2010 and displayed until 23-May-2012

Reasons for adding or updating:

  • Change to warnings or special precautions for use

Updated on 19-Aug-2009 and displayed until 24-May-2010

Reasons for adding or updating:

  • Change to date of revision

Updated on 16-May-2008 and displayed until 19-Aug-2009

Reasons for adding or updating:

  • Change due to user-testing of patient information

Updated on 19-Sep-2007 and displayed until 16-May-2008

Reasons for adding or updating:

  • Change to Further Information section

Updated on 02-Aug-2006 and displayed until 19-Sep-2007

Reasons for adding or updating:

  • Change to side-effects

Updated on 04-Aug-2005 and displayed until 02-Aug-2006

Reasons for adding or updating:

  • Change to warnings or special precautions for use
  • Change to side-effects

Updated on 05-Dec-2000 and displayed until 25-May-2001

Reasons for adding or updating:

  • No reasons supplied

Updated on 18-Jan-2000 and displayed until 05-Dec-2000

Reasons for adding or updating:

  • No reasons supplied

Company contact details

SANOFI

Company image
Address

1 Onslow Street, Guildford, Surrey, GU1 4YS, UK

Fax

+44 (0)1483 535 432

Medical Information e-mail
Telephone

+44 (0)1483 505 515

Medical Information Direct Line

+44 (0)845 372 7101

Before you contact this company: often several companies will market medicines with the same active ingredient. Please check that this is the correct company before contacting them. Why?

Active ingredients

leflunomide

Legal categories

POM - Prescription Only Medicine

This site uses cookies. By continuing to browse the site you are agreeing to our policy on the use of cookies. Continue